Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTNNB1 | P35222 | 8/20 | 0.48 |
| ▸ | WNT3A | P56704 | 8/20 | 0.48 |
| ▸ | RAB9A | P51151 | 5/20 | 0.46 |
| ▸ | NPC1 | O15118 | 4/20 | 0.46 |
| ▸ | TAS1R3 | Q7RTX0 | 3/20 | 0.46 |
| ▸ | TAS1R1 | Q7RTX1 | 3/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | PRKCI | P41743 | 1/20 | 0.45 |
| ▸ | ACHE | P22303 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | CLK1 | P49759 | 1/20 | 0.43 |
| ▸ | PTGER3 | P43115 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6794489 | 0.88 | NPC1 (0.59) | CTNNB1WNT3ARAB9ANPC1PKM | |
| SCHEMBL4032725 | 0.82 | KDM4E (0.56) | CTNNB1WNT3ARAB9ANPC1PKM | |
| SCHEMBL6871504 | 0.78 | RAB9A (0.47) | CTNNB1WNT3ARAB9ANPC1TAS1R3 | |
| SCHEMBL1091802 | 0.76 | ATM (0.69) | CTNNB1WNT3ARAB9ANPC1TAS1R3 | |
| SCHEMBL14044259 | 0.74 | PRKCI (0.58) | CTNNB1WNT3ARAB9ANPC1TAS1R3 | |
| SCHEMBL11022828 | 0.73 | HPGD (0.70) | CTNNB1WNT3ATAS1R3TAS1R1PKM | |
| SCHEMBL6181845 | 0.73 | PRKCI (0.57) | CTNNB1WNT3ARAB9ANPC1TAS1R3 | |
| SCHEMBL1182701 | 0.73 | PRKCI (0.57) | CTNNB1WNT3ARAB9ANPC1TAS1R3 | |
| SCHEMBL14592085 | 0.72 | MEN1 (0.48) | RAB9ANPC1KDM4ESMN1; SMN2 | |
| SCHEMBL5199273 | 0.72 | GRM5 (0.55) | RAB9ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040152738-A1 | Pyridyl-substituted triazoles as tgf inhibitors | SMITHKLINE BEECHAM CORPORATION | 2004-08-05 | — | — | US | disclosed |
| EP-1335916-A1 | PYRIDYL-SUBSTITUTED TRIAZOLES AS TGF INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2003-08-20 | — | — | EP | disclosed |
| WO-2002040476-A1 | PYRIDYL-SUBSTITUTED TRIAZOLES AS TGF INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2002-05-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040152738-A1 | Pyridyl-substituted triazoles as tgf inhibitors | TGFBR1, TGFBR2, SMAD3 | CTNNB1 833/4885WNT3A 1064/4885RAB9A 3867/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.